ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L19

Kellgren-Lawrence Grade (KL) 0 Vs. KL 1 Knees Differ in Their MRI Predictors of Subsequent Radiographic Osteoarthritis

C.Kent Kwoh1, Ali Guermazi2, Tomoko Fujii3, Robert M. Boudreau3, Michael Hannon4, Jason Grago4, David Hunter5, Felix Eckstein6 and Frank Roemer7, 1Department of Medicine, The University of Arizona Arthritis Center, Tucson, AZ, 2Radiology, Boston University School of Medicine, Boston, MA, 3Epidemiology, University of Pittsburgh, Pittsburgh, PA, 4Medicine, University of Pittsburgh, Pittsburgh, PA, 5University of Sydney, Sydney, Australia, 6Paracelsus Medical University, Salzburg, Austria, 7Klinikum Augsburg, Augsburg, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Knee, MRI, osteoarthritis and radiography

  • Tweet
  • Email
  • Print
Session Information

Title: ACR Late-Breaking Abstract Poster Session

Session Type: Late-Breaking Abstracts

Background/Purpose:

Kellgren-Lawrence grade (KL) 1, defined by a questionable osteophyte and/or doubtful joint space narrowing, is thought to be an intermediate stage from non-OA (i.e., KL 0) to definite radiographic osteoarthritis (i.e., KL ≥2, ROA). MRI allows the identification of specific structural changes in joint tissues that precede the development of ROA. We examined whether the morphologic changes on MRI that precede ROA differ for knees that are KL 0 vs. those that are KL 1.

Methods:

The participants in this nested case-control study were from the Osteoarthritis Initiative (OAI) cohort with risk factors for OA but not ROA in the target knee (i.e., KL 0 or 1) at baseline. Participants were assessed by knee radiographs and non-contrast 3T MRI using the OAI protocol. Baseline MRIs were assessed for Hoffa-synovitis, effusion-synovitis, bone marrow lesions (BMLs), meniscal damage or meniscal extrusion using the MRI Osteoarthritis Knee Score (MOAKS). Case knees were those that developed definite ROA on the PA fixed flexion radiographs at the 12M, 24M, 36M or 48M OAI visits. The control knees (i.e., did not develop incident ROA over the four-year period) were 1:1 matched by age (within five years), sex, and baseline KL in the target knee and the contralateral knee (e.g., KL 0/0, 0/1/, 1/1, 0/2, or 1/2).  Conditional Logistic Regression was used to estimate the odds ratios (OR) of subsequent incident ROA for each of the MRI features.

Results:

355 knees that developed ROA (67% female) were matched to 355 controls with a mean age of 60.1 (SD 8.5). The majority were overweight: mean body mass index was 28.9 (SD 4.5) in cases and 27.7 (SD 4.4) in controls. For knees that were KL 0 at baseline (n=133 cases/controls pairs), the MRI predictors of subsequent ROA were Hoffa synovitis (OR 1.80 and 95% CI [1.10-2.94]); meniscal damage (tear or maceration) in the posterior medial horn (OA 4.11 [1.98-8.52] or the anterior lateral horn (OR 9.00 [1.14-71.04]); and number of subregions in the medial compartment with meniscal tear or extrusion (n=1 subregions, OR 4.14 [1.86-9.25], ≥2, OR 4.42 [1.46-13.43]. For knees that were KL 1 at baseline (n=222 cases/controls pairs), the MRI predictors of subsequent ROA were Hoffa synovitis (OR 1.97 [1.31-2.96]; effusion-synovitis (OR 1.65 and [1.11-2.44]; lateral meniscal extrusion (OR 2.80 [1.01-7.77]; and number of BMLs (=1, OR 1.98 [1.22-3.20]; =2, OR 2.20 [1.31-3.68]; and ≥3, OR 2.21 [1.22-4.02]). Only 27/133 (20%) of KL 0 knees at baseline were KL1 at any reading before being KL ≥2.  

Conclusion:

The altered joint determinants on MRI that precede the development of ROA differ for KL 0 knees vs. KL1 knees suggesting that different tissues are involved at the different stages of OA development.   These findings have important implications for the development of potential preventative and/or disease modifying OA drugs (DMOADs). 


Disclosure:

C. K. Kwoh,

Pfizer Inc,

5;

A. Guermazi,

Boston Imaging Core Lab,LLC,

1,

MerckSerono, TissueGene,Sanofi-Aventis,

5;

T. Fujii,
None;

R. M. Boudreau,
None;

M. Hannon,
None;

J. Grago,
None;

D. Hunter,
None;

F. Eckstein,

Chondrometrics,

3,

Chondrometrics,

1,

MerckSerono, AbbVie,

5,

MerckSerono, Synarc, Abbvie, Kolon,

2;

F. Roemer,

Boston Imaging Core Lab,LLCl,

1.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kellgren-lawrence-grade-kl-0-vs-kl-1-knees-differ-in-their-mri-predictors-of-subsequent-radiographic-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology